Next Article in Journal
Genetic Diversity Among Wild and Cultured Bighead Carp (Hypophthalmichthys nobilis) in the Middle Yangtze River by Microsatellite Markers
Previous Article in Journal
Understanding Glycogen Storage Disease Type IX: A Systematic Review with Clinical Focus—Why It Is Not Benign and Requires Vigilance
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Genes
Volume 16
Issue 5
10.3390/genes16050585
genes-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Pontocerebellar Hypoplasia Type 1 and Associated Neuronopathies

by
Mario Škarica
1,
Gyula Acsadi
2,3,4 and
Sasha A. Živković
5,*
1
Department of Psychiatry, Yale School of Medicine, New Haven, CT 06510, USA
2
Division of Neurology, Connecticut Children’s Medical Center, St. Hartford, CT 06106, USA
3
Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT 06030, USA
4
Department of Neurology, University of Connecticut School of Medicine, Farmington, CT 06030, USA
5
Department of Neurology and CMT Program at Yale, Yale School of Medicine, New Haven, CT 06510, USA
*
Author to whom correspondence should be addressed.
Genes 2025, 16(5), 585; https://doi.org/10.3390/genes16050585
Submission received: 30 April 2025 / Revised: 11 May 2025 / Accepted: 14 May 2025 / Published: 15 May 2025
(This article belongs to the Section Neurogenomics)
Browse Figure
Versions Notes

Abstract

:
Pontocerebellar hypoplasia is a rare neurodegenerative syndrome characterized by severe hypoplasia or atrophy of pons and cerebellum that may be associated with other brain malformations, microcephaly, optic nerve atrophy, dystonia, ataxia and neuromuscular disorders. At this time, there are 17 variants of PCH distinguished by clinical presentation and distinctive radiological and biochemical features in addition to pontine and cerebellar hypoplasia. PCH1 is defined as PCH variant associated with anterior horn degeneration in the spinal cord with muscle weakness and hypotonia, and is associated with recessive variants in genes VRK1, EXOSC3, EXOSC8, EXOSC9 and SLC25A46. Neuromuscular manifestations may clinically present as amyotrophic lateral sclerosis (ALS), motor neuropathy (HMN) or neuronopathy (non-5q spinal muscular atrophy; SMA) or sensorimotor polyneuropathy (HMSN). Physiologic functions of PCH1-associated genes include regulation of RNA metabolism, mitochondrial fission and neuronal migration. Overall, complex phenotypes associated with PCH1 gene variants ranging from PCH and related neurodevelopmental disorders combined with neuromuscular disorders to isolated neuromuscular disorders have variable outcomes with isolated neuromuscular disorders typically having later onset with better outcomes. Improved understanding of pathogenesis of pontocerebellar hypoplasia and its association with motor neuronopathies and peripheral neuropathies may provide us with valuable insights and lead to potential new therapeutic targets for neurodegenerative disorders.

1. Introduction

Pontocerebellar hypoplasia (PCH) is a rare neurodegenerative syndrome characterized by severe hypoplasia or atrophy of pons and cerebellum that may be associated with other brain malformations, microcephaly, optic nerve atrophy, dystonia, ataxia and neuromuscular disorders [1,2]. The exact overall incidence and prevalence of PCH are unknown. The incidence of one of its more frequent variants PCH2A was estimated at less than 1 in 200,000 [3]. The first classification of PCH by Barth in 1993. recognized 2 variants, PCH1 associated with spinal muscular atrophy and PCH2 associated with dystonia without anterior horn cell injury [4]. At this time, there are 17 variants of PCH distinguished by clinical presentation and distinctive radiological and biochemical features in addition to pontine and cerebellar hypoplasia [1,2]. PCH1 is defined as PCH variant associated with anterior horn degeneration in the spinal cord with muscle weakness and hypotonia [1,5]. The first detailed description of anterior horn cell disease with pontocerebellar hypoplasia in infants was provided by Goutieres in 1977, and since then recessive variants in five genes have been identified as causes of PCH1, including VRK1, EXOSC3, EXOSC8, EXOSC9 and SLC25A46 [1,5,6]. Earlier cases of infantile spinal amyotrophy with cerebellar abnormalities were considered as atypical cases of Werdnig-Hoffman disease [7]. Neuromuscular manifestations associated with variants of PCH1-related genes may clinically present as amyotrophic lateral sclerosis (ALS), motor neuropathy (HMN) or neuronopathy (non-5q spinal muscular atrophy; SMA) or sensorimotor polyneuropathy (HMSN) [1]. Electrodiagnostic testing (electromyography and nerve conduction studies are helpful to demonstrate peripheral nervous system abnormalities, and muscle biopsy typically shows neurogenic atrophy, although myopathic-like changes have been reported as well [8,9,10,11,12,13,14,15,16]. Physiologic functions of PCH1-associated genes include regulation of RNA metabolism, mitochondrial fission and neuronal migration, while genes associated with other PCH variants also play roles in tRNA splicing, RNA processing, regulation of GTP and selenocysteine synthesis and intracellular vesicle transport [1].
Typically, PCH manifests early with very limited or no developmental progress and poor survival [1]. In addition to early onset of neurodegenerative syndromes, recessive variants in PCH1-associated genes may also manifest in adulthood with isolated neuromuscular disorders. The age of onset is variable but the patients with motor and sensorimotor neuropathies without central nervous system abnormalities typically present much later than patients with fully manifesting PCH1 or combination of PCH1 and peripheral nerve disorders. In addition to biallelic autosomal recessive variants, PCH1 cases with compound heterozygosity have been reported as well [13,17].
We review clinical manifestations of gene variants associated with PCH1 and associated peripheral nervous system complications.

2. Genes

Genes associated with PCH1 variants include VRK1 (PCH1A), EXOSC3/EXOSC8/EXOSC9 (PCH1B-D) and SLC25A46 (PCH1E), and participate in regulation of neuronal migration, mRNA maturation and surveillance, and mitochondrial fission/fusion [1].

2.1. Vaccinia-Related Kinase 1 (VRK1; OMIM *602168)

The VRK1 gene (chromosome 14q32) encodes a serine/threonine kinase. VRK1 is highly expressed in and central and peripheral nervous system and in highly proliferative cells, such as those in testis, thymus and fetal liver. VRK1 participates in regulation of gene transcription, chromatin remodeling and DNA damage response as it interacts with histones and various transcription factors [18,19]. VRK1 interacts with multiple proteins including p53 and histones. Pathogenic variants of VRK1 have been associated with various neurodevelopmental and neuromuscular disorders, including pontocerebellar hypoplasia (PCH1A), microcephaly, motor and sensorimotor neuropathies and motor neuron disorders. With dominant expression in cell nucleus, it interacts with chromatin, several transcription factors and regulates several cellular processes, including the cell cycle, gene transcription, DNA damage responses, chromatin remodeling, and the assembly of Cajal bodies [18,20]. All VRK1 pathogenic variants are recessive—patients with clinical presentation are either homozygous or compound heterozygous. Functional analyses confirmed diminished levels of VRK1 protein and changes in RNA processing. VRK1 pathogenic variants are associated with pontocerebellar hypoplasia (PCH1A), microcephaly, SMA, ALS, HMN and HMSN.

2.2. Nuclear RNA Exosome Complex Components 3, 8 and 9 (EXOSC 3; OMIM *606489, EXOSC8; OMIM *606019, EXOSC9; OMIM *606180)

EXOSC3, EXOSC8, EXOSC9 genes (chromosomes 9p13.2, 13q13.3, 4q27, respectively) encode structural (non-catalytic component) subunits of RNA exosome, a multiunit ribonuclease complex. Eukaryotic RNA exosome is evolutionary conserved complex consisting of 10–111 subunits located in nucleus and cytosol and is crucial for both processing and degradation of a variety of RNAs, particularly in development and cell differentiation [21]. The exosome has a capacity to degrade any RNA but the activity of the isolated complex is weak. The activity is influenced by the cofactors and the RNA structures and it plays a role in controlling expression levels of specific mRNAs in response to environmental cues and during cell differentiation and development [21]. Variants of exosome component 3 (EXOSC3), exosome component 8 (EXOSC8) and exosome component 9 (EXOSC9) have all been associated with pontocerebellar hypoplasia type 1 (PCH1B-D). Clinical manifestations of EXOSC3/8/9 variants include PCH1B-D, microcephaly, optic atrophy, HMN and SMA.

2.3. Solute Carrier Family 25, Member 46 (SLC25A46; OMIM *610826)

SLC25A46 (chromosome 5q22.1) belongs to the SLC25 family of mitochondrial carrier proteins and is coded by nuclear genes. The proposed functions of SLC25A46 include facilitation of lipid transport across mitochondrial membrane at contact sites between mitochondria and endoplasmatic reticulum [22,23]. Mitochondrial fission is essential for mitochondrial division (proliferation) and the maintenance of its quality control [24]. SLC25A46 must be imported in inner mitochondrial membrane where it plays a role in mitochondrial network maintenance (fusion-fission balance) [23,24,25]. In autophagy, it is a part of mitochondrial-derived compartments (MDCs) which regulate the recycling of selective outer and inner mitochondrial membrane proteins (SLC25A46) within lysosomes [23]. In mammals, SLC25A46 facilitates lipid transport from endoplasmic reticulum to mitochondria in order to maintain mitochondrial cristae [26,27]. In yeast overexpression systems, SLC25A46 interacts with mitofusin 2 (MFN2) and optic atrophy 1 (Opa1) genes which are associated with CMT2A (MFN2) and optic atrophy (Opa1) [22,23,25]. Variants in SLC25A46 are associated with PCH1E, and other manifestations include HMSN, optic atrophy, ataxia and Leigh syndrome [26]. Loss of function of SLC25A46 is associated with lethal PCH, contrasting other variants causing non-lethal optic atrophy [28].

3. Clinical Phenotypes

3.1. Pontocerebellar Hypoplasia Type 1 and Spinal Muscular Atrophy (PCH1-SMA)

In PCH1 associated with SMA, early onset of symptoms prenatally or at birth manifests with severe weakness and hypotonia, and these patients may die within first few months [8]. Later onset of symptoms is associated with prolonged survival ranging from 2 to 11 years, or well into their fifth decade [18,29,30]. Spectrum of other associated clinical symptoms includes polyhydramnios, congenital contractures, severe muscle hypotonia with respiratory failure, spasticity, hearing and vision impairment and psychomotor retardation. In addition to pontocerebellar hypoplasia, neuroimaging studies may also show thinning of corpus callosum, cortical atrophy and delayed myelination [30]. Electrodiagnostic testing of infants is often challenging. Nerve conduction studies show reduced amplitudes of motor responses with normal sensory nerve conduction studies (or may be normal), and needle electromyography reveals neurogenic chronic motor unit changes. If performed, muscle biopsies typically show neurogenic muscle atrophy. Neuromuscular symptoms include weakness leading to ambulation loss and even respiratory failure. PCH variants associated with motor neuron degeneration have been reported with variants of all genes associated with PCH1 (VRK1, EXOSC3/EXOSC8/EXOSC9, SLC2A46) (Table 1) [1].

3.2. Hereditary Motor Neuropathy and Motor Neuron Disorders Without Neurodevelopmental Abnormalities

Variants of PCH1-associated genes have been recognized as some of potential causes of non-5Q-SMA and other motor nerve/neuron disorders in the absence of neurodevelopmental abnormalities [31]. Hereditary motor neuropathies and non-5Q SMA are similar neuromuscular disorders with overlapping phenotypes manifesting with hyporeflexia, muscle weakness and without sensory symptoms [31]. Nerve conduction studies show reduced amplitudes of motor responses with normal sensory nerve conduction studies (or may be normal), and needle electromyography reveals neurogenic chronic motor unit changes. As in PCH1-SMA, muscle biopsies typical show chronic neurogenic changes. The onset of weakness may be distal or proximal, and respiratory muscles may be involved as well. Some patients with motor neuronopathies may exhibit signs of upper motor neuron dysfunction as well and are diagnosed with ALS [32]. Clinical course of VRK1-associated motor neuron disease may reveal very slow rate of progression with extended survival, even with childhood onset [32,33]. The onset of motor neuropathy may be early or late in the adulthood [15,16,29]. Motor neuron disorders and motor neuropathies without neurodevelopmental abnormalities have been reported with PCH1A (VRK1 gene) [10,16,32,34].

3.3. Sensorimotor Axonal Polyneuropathy with or Without Neurodevelopmental Abnormalities

There is a considerable overlap between axonal CMT (CMT2) and other neuromuscular and neurologic disorders and variants in same genes can manifest as either hereditary motor neuropathies, hereditary spastic paraparesis or hereditary axonal sensorimotor neuropathies (CMT2) [10,16,35]. Nerve conduction studies demonstrate sensory and motor abnormalities that would distinguish sensorimotor polyneuropathy from motor neuropathy and motor neuronopathies with exclusively motor abnormalities. Axonal sensorimotor neuropathy has been reported in patients with pontocerebellar hypoplasia and SLC25A46 variants (PCH1E), and may be overshadowed by other severe neurologic symptoms with early onset and short survival [28,30].
Variants of VRK1 may cause sensorimotor neuropathy without neurodevelopmental abnormalities with an onset after the age of 40 with a slow gradual progression [10,16,34]. Variants of SLC25A46 may present with sensorimotor polyneuropathy with or without neurodevelopmental abnormalities, and the absence of neurodevelopmental abnormalities usually indicates prolonged survival. However, both early mortality and extended survival have been reported with SLC5A46 variants with neurodevelopmental abnormalities.

4. Discussion

Variants of PCH1-associated genes can be associated with phenotypes ranging from severe neurodevelopmental disorders like PCH with or without neuromuscular and movement disorders, to motor neuron and peripheral nerve disorders without obvious signs of abnormal neurodevelopment. Neuromuscular phenotypes of variants of PCH1-associated genes belong to a wide spectrum of complex inherited neuropathies where peripheral nervous system disorders are only one of manifestations of complex clinical syndromes [36]. Early onset is typically associated with more severe disorders, especially with concurrent neurodevelopmental abnormalities. Later onset may be associated with slowly progressive milder syndromes and forme fruste manifestations, even in the presence of some neurodevelopmental abnormalities. Currently, our understanding of phenotype-genotype correlation in PCH-associated disorders and the impact of post-translational modifications on clinical manifestations remains limited. Recessive inheritance is required for all PCH1 variants, as either homozygous or compound heterozygous variants. Certain VRK1 variants (Arg 39 and Val236) seem to present with neurodevelopmental abnormalities only with homozygous variants, while compound heterozygous variants have only neuromuscular manifestations (Table 1). Nevertheless, due to paucity of cases, this may only represent a coincidence. Pathogenesis of PCH1 may follow two distinct molecular pathways associated with (a) destabilization of the protein leading to its depletion and (b) interference with its molecular actions (e.g., phosphorylation) as described with VRK1 and SLC25A46 variants [19,37]. In an experimental model of PCH1B in zebrafish, knockdown of EXOSC3 by antisense morpholinos led to a phenotype with a short curved spine and small brain. Co-treatment of zebrafish with wildtype EXOSC3 mRNA led to phenotype rescue [38]. Research studies have demonstrated interactions between various genes associated with PCH1 suggesting shared pathway mechanism(s), involving the dysfunction of cell cycle progression and mitochondrial dynamics (Figure 1) [18,21,24,37]. There is an overlap of pathophysiology of mechanisms leading to PCH1 and motor neuron disorders involving RNA processing and mitochondrial dysfunction which may potentially explain concomitant motor neuron injury manifesting as juvenile ALS, spinal muscular atrophy or hereditary motor neuropathy [39,40]. Laboratory studies showed evidence of overlapping patterns of mitochondrial dysfunction associated with PCH1A, PCH1B and PCH1E leading to increased mitochondrial hyperfusion, impaired mtDNA replication and metabolic glycolytic shift (Figure 1) [22,25,41,42]. The role of mitochondrial dysfunction in the degeneration of motor neurons in ALS has been proposed but its clinical significance and underlying mechanisms still remain unclear [43]. RNA processing abnormalities are associated with neurodevelopmental abnormalities and motor neuron disorders, and cytoplasmic aggregates of RNA-binding protein TDP43 are found across different variants of ALS [40].
Additionally, in some other PCH variants, rhabdomyolysis (PCH4) and weakness with hypotonia (PCH4 and PCH7) are also suggestive of neuromuscular involvement, but additional clinical information would be needed to characterize the involvement of peripheral nervous system [44,45,46].
Overall, complex phenotypes associated with PCH1 gene variants ranging from PCH and related neurodevelopmental disorders combined with neuromuscular disorders to isolated neuromuscular disorders have variable outcomes with isolated neuromuscular disorders typically having later onset with better outcomes (Table 1). The PCH1-related group of genes associated with pontocerebellar hypoplasia and peripheral nerve/motor neuron disorders shares physiologic roles of controlling cell cycle progression and mitochondrial dynamics (Figure 1). The connection between pontine and cerebellum development and motor neuron disorders is not well understood, but cerebellar atrophy has been demonstrated in various neurodegenerative conditions, including ALS [47]. Improved understanding of pathogenesis of pontocerebellar hypoplasia and its association with motor neuronopathies and peripheral neuropathies may provide us with valuable insights and lead to potential new therapeutic targets for neurodegenerative disorders. Currently, there is no treatment for PCH, including PCH1, but gene replacement therapies may be considered for these recessive disorders.
Table 1. Variants of PCH1-associated genes manifesting with neuromuscular disorders.
Table 1. Variants of PCH1-associated genes manifesting with neuromuscular disorders.
GeneBase Pair MutationAminoAcid SubstitutionOnset (Outcome)Imaging/CNS PhenotypeNMD PhenotypeReference
VRK1c.197C>G (he); c.583T>G (he)p.Ala66Gly; p.Leu195ValAdult (alive at 48 yr)UnkSMA[9]
c.265C>T (he); c.769G>A (he)p.Arg89*; p.Gly257SerChildhood (alive at 27 yr)NormalALS[32]
C.266G>A (he); c.706G>A (he)p.Arg89Gln; p.Val236MetInfancy (alive at 9 and 10 yr)MicrocephalyHMSN[35]
c.356A>G (he); c.961C>T(he)p.His119Arg; p.Arg321CysAdult (alive at 32 yr)UnkALS[11]
c.356A>G (he); c.1072C>T (he)p.His119Arg;
p.Arg 358*		Teenage (alive at 56 yr)Brain atrophySMA[34]
c.398G>A (he); c.727G>A (he)p.Arg133His; p.Asp243AsnTeenage (alive at 28 and 33 yr)NormalHMN[16]
c.403G>A (he); c.583T>G (he)p.Gly135Arg; p.Leu195ValChildhood (alive at 20 yr)NormalALS[34]
c.583T>G (he); c.701A>G (he)p.Leu195Val; p.Asn234SerAdult (alive at 37 yr)UnkSMA[9]
c.607C>T (he); c.858G>T (he)p.Arg203Trp; p.Met286IleAdult (alive at 59 yr)UnkSMA[9]
c.637T>C (ho)p.Tyr213HisChildhood (alive at 35 yr)UnkHMSN[48]
c.706G>A (he); c.961C>T (he)p.Val236Met; p.Arg321CysAdult (alive at 51 yr)NormalSMA[15]
c.710-14T>C (he); c.721C>T (he)Intron; p.Arg241CysChildhood (alive at 28 yr)NormalALS[32]
c.767C>T (he); c.800A>G (he)p.Thr256Ile; p.Asp267GlyChildhood (alive at 24 yr)Normal #ALS[33]
c.788A>G (ho)p.Asp263GlyChildhood (alive at 25 and 29 yr)Minimal cerebellar atrophy and normalHSP[49]
c.961C>T (ho)p.Arg321CysAdult, Teenage (alive at 55 yr)Unk; NormalHMN, SMA[12,15]
c.1072C>T (ho)p.Arg358*Antenatal (died at 9.5 and 11 yr) Toddler (alive at 10 yr)PCH, microcephaly, Lissencephaly SMA, HMSN [30,35]
c.1124G>A (ho)p.Trp375*Teenage (alive at 37, 42 and 46 yr)NormalSMA, HMN[50,51]
c.1159+1G>A (ho)p.Arg387Hisfs*7Infancy, Childhood (died at 13 yr, alive at 32 yr)NormalALS, SMA[52]
c.1160G>A (ho)p.Arg387HisTeenage (alive at 49 yr), Adult (alive at 59 and 61 yr)Unk; NormalHMSN; HMN[10,16]
EXOSC3c.92G>C (ho)p.Gly31AlaInfancy (died at 4 d–17 mo.)PCH, microcephalySMA[5,17]
c.325-4_329dupGTAGTATGT
(he); c.334G>A (he)
c.395A>C (he)		p.Pro111*; p.Val112Ile; p.Asp132AlaInfancy (died at 6 mo.)PCHSMA[17]
c.325T>A (he)
c.395A>C (he)		p.Tyr109Asn; p.Asp132AlaInfancy (died at 8.5 mo)PCHSMA[17]
c.395A>C (ho)p.Asp132AlaInfancy (died at 5 d–12 yr)PCH, progressive microcephaly, cerebellar atrophy, ALS, SMA[17,38,42,53]
c.395A>C (he);
g.del37781240-37787410 (he)		p.Asp132Ala; intron. Deletion of exons 1–3Infancy (died at 6 mo.)PCH, optic atrophySMA[17]
c.404G>A (ho)p.Gly135GluInfancy (died at 2 mo)PCHSMA[17]
EXOSC8c.238 G>A (ho)p.Val80IleBirth (alive at 3 yr)PCH, hypoplastic temporal lobesSMA[54]
c.390+1delG (he); c.628C>T (he); c.815G>T (he)p.Ser116LysfsTer27; p.Pro210Ser; p.Ser272ThrInfant (alive at 16 yr)PCHSMA[13]
c.815 G>C (ho)p.Ser272ThrInfancy (died at 9–19 mo.)PCHSMA[55]
EXOSC9c.41T>C (ho)p.Leu14ProInfant (died at 8–10 mo)Cerebellar atrophy, SMA, HMN[56,57]
c.41T>C (he); c.481C>T (he)p.Leu14Pro; p.Arg161*Infant (died at 10 mo.)Cerebellar atrophy, CNS dysmyelination,HMN[57]
c.151G>C (ho)p.Gly51ArgInfant (died at 2 mo.)Cerebellar atrophySMA[14]
c.239T>G (he); c.484dupA (he)p.Gly51Arg; p.Arg162Lysfs*3Toddler (alive at 6 yr, died at 10 yr)Cerebellar atrophy, normal ponsSMA[14]
SLC25A46c.42C>G (he); c.462+
1G>A (he)		p.Tyr14*;(intron)Infant (died at 1–18 d)PCHSMA[8]
c.165_165insC (he);
c.746G>A (he),		p.[His56fs*94];
[Gly249Asp]		Childhood (alive at 43 yr)NormalHMSN[22]
c.413 T>G (ho)p.Leu138ArgInfant (alive at 15 yr)Cerebellar atrophy, progressive myoclonic ataxiaHMSN[58]
c.1018C>T (ho)p.Arg340CysToddler (alive at 51yr)Cerebellar atrophyHMSN[22,59]
c.1022T>C (ho)p.Leu341ProInfant (died at 2–6 wk)PCH, optic atrophy, hypotonia, seizuresHMSN[28]
ALS—amyotrophic lateral sclerosis; HMN—hereditary motor neuropathy; HMSN—hereditary motor-sensory neuropathy; PCH—pontocerebellar hypoplasia; SMA—spinal muscular atrophy; d—days; mo—months; wk—weeks; yr—years; unk—unknown; he—heterozygous; ho—homozygous; #—incidental pineal cyst.

Author Contributions

Conceptualization, M.Š. and S.A.Ž.; methodology, G.A., S.A.Ž.; writing—original draft preparation, S.A.Ž.; writing—M.Š., G.A., S.A.Ž.; visualization, S.A.Ž. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. van Dijk, T.; Baas, F.; Barth, P.G.; Poll-The, B.T. What’s new in pontocerebellar hypoplasia? An update on genes and subtypes. Orphanet J. Rare Dis. 2018, 13, 92. [Google Scholar] [CrossRef] [PubMed]
  2. Rusch, C.T.; Bolsterli, B.K.; Kottke, R.; Steinfeld, R.; Boltshauser, E. Pontocerebellar hypoplasia: A pattern recognition approach. Cerebellum 2020, 19, 569–582. [Google Scholar] [CrossRef] [PubMed]
  3. Sanchez-Albisua, I.; Frolich, S.; Barth, P.G.; Steinlin, M.; Krageloh-Mann, I. Natural course of pontocerebellar hypoplasia type 2A. Orphanet J. Rare Dis. 2014, 9, 70. [Google Scholar] [CrossRef] [PubMed]
  4. Barth, P.G. Pontocerebellar hypoplasias. An overview of a group of inherited neurodegenerative disorders with fetal onset. Brain Dev. 1993, 15, 411–422. [Google Scholar] [CrossRef] [PubMed]
  5. Ivanov, I.; Atkinson, D.; Litvinenko, I.; Angelova, L.; Andonova, S.; Mumdjiev, H.; Pacheva, I.; Panova, M.; Yordanova, R.; Belovejdov, V.; et al. Pontocerebellar hypoplasia type 1 for the neuropediatrician: Genotype-phenotype correlations and diagnostic guidelines based on new cases and overview of the literature. Eur. J. Paediatr. Neurol. 2018, 22, 674–681. [Google Scholar] [CrossRef] [PubMed]
  6. Goutieres, F.; Aicardi, J.; Farkas, E. Anterior horn cell disease associated with pontocerebellar hypoplasia in infants. J. Neurol. Neurosurg. Psychiatry 1977, 40, 370–378. [Google Scholar] [CrossRef] [PubMed]
  7. Norman, R.M. Cerebellar hypoplasia in Werdnig-Hoffmann disease. Arch. Dis. Child. 1961, 36, 96–101. [Google Scholar] [CrossRef] [PubMed]
  8. Braunisch, M.C.; Gallwitz, H.; Abicht, A.; Diebold, I.; Holinski-Feder, E.; Van Maldergem, L.; Lammens, M.; Kovacs-Nagy, R.; Alhaddad, B.; Strom, T.M.; et al. Extension of the phenotype of biallelic loss-of-function mutations in SLC25A46 to the severe form of pontocerebellar hypoplasia type I. Clin. Genet. 2018, 93, 255–265. [Google Scholar] [CrossRef] [PubMed]
  9. Demaegd, K.; Brilstra, E.H.; Hoogendijk, J.E.; de Bie, C.I.; de Pagter, M.S.; van Hecke, W.; Muhlebner, A.; van Es, M.A.; Milone, M.; van Rheenen, W. Distal spinal muscular atrophy featured by predominant calf muscle involvement in VRK1 associated disease—Case series and review. Neuromuscul. Disord. 2022, 32, 527–532. [Google Scholar] [CrossRef] [PubMed]
  10. Greenbaum, L.; Barel, O.; Nikitin, V.; Hersalis-Eldar, A.; Kol, N.; Reznik-Wolf, H.; Dominissini, D.; Pras, E.; Dori, A. Identification of a homozygous VRK1 mutation in two patients with adult-onset distal hereditary motor neuropathy. Muscle Nerve 2020, 61, 395–400. [Google Scholar] [CrossRef] [PubMed]
  11. Nguyen, T.P.; Biliciler, S.; Wiszniewski, W.; Sheikh, K. Expanding phenotype of VRK1 mutations in motor neuron disease. J. Clin. Neuromuscul. Dis. 2015, 17, 69–71. [Google Scholar] [CrossRef] [PubMed]
  12. Previtali, S.C.; Zhao, E.; Lazarevic, D.; Pipitone, G.B.; Fabrizi, G.M.; Manganelli, F.; Mazzeo, A.; Pareyson, D.; Schenone, A.; Taroni, F.; et al. Expanding the spectrum of genes responsible for hereditary motor neuropathies. J. Neurol. Neurosurg. Psychiatry 2019, 90, 1171–1179. [Google Scholar] [CrossRef] [PubMed]
  13. Rodriguez-Garcia, M.E.; Cotrina-Vinagre, F.J.; Bellusci, M.; Merino-Lopez, A.; Chumilla-Calzada, S.; Garcia-Silva, M.T.; Martinez-Azorin, F. New subtype of PCH1C caused by novel EXOSC8 variants in a 16-year-old Spanish patient. Neuromuscul. Disord. 2021, 31, 773–782. [Google Scholar] [CrossRef] [PubMed]
  14. Sakamoto, M.; Iwama, K.; Sekiguchi, F.; Mashimo, H.; Kumada, S.; Ishigaki, K.; Okamoto, N.; Behnam, M.; Ghadami, M.; Koshimizu, E.; et al. Novel EXOSC9 variants cause pontocerebellar hypoplasia type 1D with spinal motor neuronopathy and cerebellar atrophy. J. Hum. Genet. 2021, 66, 401–407. [Google Scholar] [CrossRef] [PubMed]
  15. Sung, A.; Moretti, P.; Shaibani, A. Adult-onset spinal muscular atrophy due to mutations in the VRK1 gene. Neurol. Genet. 2021, 7, e599. [Google Scholar] [CrossRef] [PubMed]
  16. Zivkovic, S.A.; Nowak, R.J.; DiCapua, D. CMT2 and distal hereditary motor neuropathy associated with VRK1 variants: Case series. Neuromuscul. Disord. 2024, 47, 105254. [Google Scholar] [CrossRef] [PubMed]
  17. Eggens, V.R.; Barth, P.G.; Niermeijer, J.M.; Berg, J.N.; Darin, N.; Dixit, A.; Fluss, J.; Foulds, N.; Fowler, D.; Hortobagyi, T.; et al. EXOSC3 mutations in pontocerebellar hypoplasia type 1: Novel mutations and genotype-phenotype correlations. Orphanet J. Rare Dis. 2014, 9, 23. [Google Scholar] [CrossRef] [PubMed]
  18. El-Bazzal, L.; Rihan, K.; Bernard-Marissal, N.; Castro, C.; Chouery-Khoury, E.; Desvignes, J.P.; Atkinson, A.; Bertaux, K.; Koussa, S.; Levy, N.; et al. Loss of Cajal bodies in motor neurons from patients with novel mutations in VRK1. Hum. Mol. Genet. 2019, 28, 2378–2394. [Google Scholar] [CrossRef] [PubMed]
  19. Martin-Doncel, E.; Rojas, A.M.; Cantarero, L.; Lazo, P.A. VRK1 functional insufficiency due to alterations in protein stability or kinase activity of human VRK1 pathogenic variants implicated in neuromotor syndromes. Sci. Rep. 2019, 9, 13381. [Google Scholar] [CrossRef] [PubMed]
  20. Lazo, P.A.; Morejon-Garcia, P. VRK1 variants at the cross road of Cajal body neuropathogenic mechanisms in distal neuropathies and motor neuron diseases. Neurobiol. Dis. 2023, 183, 106172. [Google Scholar] [CrossRef] [PubMed]
  21. Kilchert, C.; Wittmann, S.; Vasiljeva, L. The regulation and functions of the nuclear RNA exosome complex. Nat. Rev. Mol. Cell Biol. 2016, 17, 227–239. [Google Scholar] [CrossRef] [PubMed]
  22. Abrams, A.J.; Hufnagel, R.B.; Rebelo, A.; Zanna, C.; Patel, N.; Gonzalez, M.A.; Campeanu, I.J.; Griffin, L.B.; Groenewald, S.; Strickland, A.V.; et al. Mutations in SLC25A46, encoding a UGO1-like protein, cause an optic atrophy spectrum disorder. Nat. Genet. 2015, 47, 926–932. [Google Scholar] [CrossRef] [PubMed]
  23. Tabara, L.C.; Segawa, M.; Prudent, J. Molecular mechanisms of mitochondrial dynamics. Nat. Rev. Mol. Cell Biol. 2025, 26, 123–146. [Google Scholar] [CrossRef] [PubMed]
  24. Adebayo, M.; Singh, S.; Singh, A.P.; Dasgupta, S. Mitochondrial fusion and fission: The fine-tune balance for cellular homeostasis. FASEB J. 2021, 35, e21620. [Google Scholar] [CrossRef] [PubMed]
  25. Boopathy, S.; Luce, B.E.; Lugo, C.M.; Hakim, P.; McDonald, J.; Kim, H.L.; Ponce, J.; Ueberheide, B.M.; Chao, L.H. Identification of SLC25A46 interaction interfaces with mitochondrial membrane fusogens Opa1 and Mfn2. J. Biol. Chem. 2024, 300, 107740. [Google Scholar] [CrossRef] [PubMed]
  26. Janer, A.; Prudent, J.; Paupe, V.; Fahiminiya, S.; Majewski, J.; Sgarioto, N.; Des Rosiers, C.; Forest, A.; Lin, Z.Y.; Gingras, A.C.; et al. SLC25A46 is required for mitochondrial lipid homeostasis and cristae maintenance and is responsible for Leigh syndrome. EMBO Mol. Med. 2016, 8, 1019–1038. [Google Scholar] [CrossRef] [PubMed]
  27. Dong, J.; Chen, L.; Ye, F.; Tang, J.; Liu, B.; Lin, J.; Zhou, P.H.; Lu, B.; Wu, M.; Lu, J.H.; et al. Mic19 depletion impairs endoplasmic reticulum-mitochondrial contacts and mitochondrial lipid metabolism and triggers liver disease. Nat. Commun. 2024, 15, 168. [Google Scholar] [CrossRef] [PubMed]
  28. Wan, J.; Steffen, J.; Yourshaw, M.; Mamsa, H.; Andersen, E.; Rudnik-Schoneborn, S.; Pope, K.; Howell, K.B.; McLean, C.A.; Kornberg, A.J.; et al. Loss of function of SLC25A46 causes lethal congenital pontocerebellar hypoplasia. Brain 2016, 139, 2877–2890. [Google Scholar] [CrossRef] [PubMed]
  29. Rudnik-Schoneborn, S.; Sztriha, L.; Aithala, G.R.; Houge, G.; Laegreid, L.M.; Seeger, J.; Huppke, M.; Wirth, B.; Zerres, K. Extended phenotype of pontocerebellar hypoplasia with infantile spinal muscular atrophy. Am. J. Med. Genet. Part A 2003, 117A, 10–17. [Google Scholar] [CrossRef] [PubMed]
  30. Renbaum, P.; Kellerman, E.; Jaron, R.; Geiger, D.; Segel, R.; Lee, M.; King, M.C.; Levy-Lahad, E. Spinal muscular atrophy with pontocerebellar hypoplasia is caused by a mutation in the VRK1 gene. Am. J. Hum. Genet. 2009, 85, 281–289. [Google Scholar] [CrossRef] [PubMed]
  31. Zambon, A.A.; Pini, V.; Bosco, L.; Falzone, Y.M.; Munot, P.; Muntoni, F.; Previtali, S.C. Early onset hereditary neuronopathies: An update on non-5q motor neuron diseases. Brain 2023, 146, 806–822. [Google Scholar] [CrossRef] [PubMed]
  32. Silva, D.P.; Soeiro, E.S.M.; Silveira, F.; Pinto, S.; Gromicho, M.; Sousa, A.B.; Leao, M.; De Carvalho, M. VRK1 variants in two Portuguese unrelated patients with childhood-onset motor neuron disease. Amyotroph. Lateral Scler. Front. Degener. 2020, 21, 291–295. [Google Scholar] [CrossRef] [PubMed]
  33. Yamaura, G.; Higashiyama, Y.; Kusama, K.; Kunii, M.; Tanaka, K.; Koyano, S.; Nakashima, M.; Tsurusaki, Y.; Miyake, N.; Saitsu, H.; et al. Novel VRK1 mutations in a patient with childhood-onset motor neuron disease. Intern. Med. 2019, 58, 2715–2719. [Google Scholar] [CrossRef] [PubMed]
  34. Stoll, M.; Teoh, H.; Lee, J.; Reddel, S.; Zhu, Y.; Buckley, M.; Sampaio, H.; Roscioli, T.; Farrar, M.; Nicholson, G. Novel motor phenotypes in patients with VRK1 mutations without pontocerebellar hypoplasia. Neurology 2016, 87, 65–70. [Google Scholar] [CrossRef] [PubMed]
  35. Gonzaga-Jauregui, C.; Lotze, T.; Jamal, L.; Penney, S.; Campbell, I.M.; Pehlivan, D.; Hunter, J.V.; Woodbury, S.L.; Raymond, G.; Adesina, A.M.; et al. Mutations in VRK1 associated with complex motor and sensory axonal neuropathy plus microcephaly. JAMA Neurol. 2013, 70, 1491–1498. [Google Scholar] [CrossRef] [PubMed]
  36. Rossor, A.M.; Haddad, S.; Reilly, M.M. The evolving spectrum of complex inherited neuropathies. Curr. Opin. Neurol. 2024, 37, 427–444. [Google Scholar] [CrossRef] [PubMed]
  37. Abrams, A.J.; Fontanesi, F.; Tan, N.B.L.; Buglo, E.; Campeanu, I.J.; Rebelo, A.P.; Kornberg, A.J.; Phelan, D.G.; Stark, Z.; Zuchner, S. Insights into the genotype-phenotype correlation and molecular function of SLC25A46. Hum. Mutat. 2018, 39, 1995–2007. [Google Scholar] [CrossRef] [PubMed]
  38. Wan, J.; Yourshaw, M.; Mamsa, H.; Rudnik-Schoneborn, S.; Menezes, M.P.; Hong, J.E.; Leong, D.W.; Senderek, J.; Salman, M.S.; Chitayat, D.; et al. Mutations in the RNA exosome component gene EXOSC3 cause pontocerebellar hypoplasia and spinal motor neuron degeneration. Nat. Genet. 2012, 44, 704–708. [Google Scholar] [CrossRef] [PubMed]
  39. Mead, R.J.; Shan, N.; Reiser, H.J.; Marshall, F.; Shaw, P.J. Amyotrophic lateral sclerosis: A neurodegenerative disorder poised for successful therapeutic translation. Nat. Rev. Drug Discov. 2023, 22, 185–212. [Google Scholar] [CrossRef] [PubMed]
  40. Faller, K.M.E.; Chaytow, H.; Gillingwater, T.H. Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2025, 21, 86–102. [Google Scholar] [CrossRef] [PubMed]
  41. Oliveira, D.; Assoni, A.F.; Alves, L.M.; Sakugawa, A.; Melo, U.S.; Teles, E.S.A.L.; Sertie, A.L.; Caires, L.C.; Goulart, E.; Ghirotto, B.; et al. ALS-associated VRK1 R321C mutation causes proteostatic imbalance and mitochondrial defects in iPSC-derived motor neurons. Neurobiol. Dis. 2024, 198, 106540. [Google Scholar] [CrossRef] [PubMed]
  42. Schottmann, G.; Picker-Minh, S.; Schwarz, J.M.; Gill, E.; Rodenburg, R.J.T.; Stenzel, W.; Kaindl, A.M.; Schuelke, M. Recessive mutation in EXOSC3 associates with mitochondrial dysfunction and pontocerebellar hypoplasia. Mitochondrion 2017, 37, 46–54. [Google Scholar] [CrossRef] [PubMed]
  43. Manfredi, G.; Xu, Z. Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion 2005, 5, 77–87. [Google Scholar] [CrossRef] [PubMed]
  44. Barth, P.G.; Ryan, M.M.; Webster, R.I.; Aronica, E.; Kan, A.; Ramkema, M.; Jardine, P.; Poll-The, B.T. Rhabdomyolysis in pontocerebellar hypoplasia type 2 (PCH-2). Neuromuscul. Disord. 2008, 18, 52–58. [Google Scholar] [CrossRef] [PubMed]
  45. Ghasemi, M.R.; Tehrani Fateh, S.; Moeinafshar, A.; Sadeghi, H.; Karimzadeh, P.; Mirfakhraie, R.; Rezaei, M.; Hashemi-Gorji, F.; Rezvani Kashani, M.; Fazeli Bavandpour, F.; et al. Broadening the phenotype and genotype spectrum of novel mutations in pontocerebellar hypoplasia with a comprehensive molecular literature review. BMC Med. Genom. 2024, 17, 51. [Google Scholar] [CrossRef] [PubMed]
  46. Wang, C.; Ge, Y.; Li, R.; He, G.; Lin, Y. Novel compound heterozygous missense variants in TOE1 gene associated with pontocerebellar hypoplasia type 7. Gene 2023, 862, 147250. [Google Scholar] [CrossRef] [PubMed]
  47. Gellersen, H.M.; Guo, C.C.; O’Callaghan, C.; Tan, R.H.; Sami, S.; Hornberger, M. Cerebellar atrophy in neurodegeneration-a meta-analysis. J. Neurol. Neurosurg. Psychiatry 2017, 88, 780–788. [Google Scholar] [CrossRef] [PubMed]
  48. Marcos, A.T.; Martin-Doncel, E.; Morejon-Garcia, P.; Marcos-Alcalde, I.; Gomez-Puertas, P.; Segura-Puimedon, M.; Armengol, L.; Navarro-Pando, J.M.; Lazo, P.A. VRK1 (Y213H) homozygous mutant impairs Cajal bodies in a hereditary case of distal motor neuropathy. Ann. Clin. Transl. Neurol. 2020, 7, 808–818. [Google Scholar] [CrossRef] [PubMed]
  49. Morejon-Garcia, P.; Keren, B.; Marcos-Alcalde, I.; Gomez-Puertas, P.; Mochel, F.; Lazo, P.A. Dysfunctional Homozygous VRK1-D263G Variant Impairs the Assembly of Cajal Bodies and DNA Damage Response in Hereditary Spastic Paraplegia. Neurol. Genet. 2021, 7, e624. [Google Scholar] [CrossRef] [PubMed]
  50. Feng, S.Y.; Li, L.Y.; Feng, S.M.; Zou, Z.Y. A novel VRK1 mutation associated with recessive distal hereditary motor neuropathy. Ann. Clin. Transl. Neurol. 2019, 6, 401–405. [Google Scholar] [CrossRef] [PubMed]
  51. Li, N.; Wang, L.; Sun, X.; Lu, Z.; Suo, X.; Li, J.; Peng, J.; Peng, R. A novel mutation in VRK1 associated with distal spinal muscular atrophy. J. Hum. Genet. 2019, 64, 215–219. [Google Scholar] [CrossRef] [PubMed]
  52. Sedghi, M.; Moslemi, A.R.; Olive, M.; Etemadifar, M.; Ansari, B.; Nasiri, J.; Emrahi, L.; Mianesaz, H.R.; Laing, N.G.; Tajsharghi, H. Motor neuron diseases caused by a novel VRK1 variant—A genotype/phenotype study. Ann. Clin. Transl. Neurol. 2019, 6, 2197–2204. [Google Scholar] [CrossRef] [PubMed]
  53. Biancheri, R.; Cassandrini, D.; Pinto, F.; Trovato, R.; Di Rocco, M.; Mirabelli-Badenier, M.; Pedemonte, M.; Panicucci, C.; Trucks, H.; Sander, T.; et al. EXOSC3 mutations in isolated cerebellar hypoplasia and spinal anterior horn involvement. J. Neurol. 2013, 260, 1866–1870. [Google Scholar] [CrossRef] [PubMed]
  54. Zaki, M.S.; Abdel-Ghafar, S.F.; Abdel-Hamid, M.S. A missense variant in EXOSC8 causes exon skipping and expands the phenotypic spectrum of pontocerebellar hypoplasia type 1C. J. Hum. Genet. 2024, 69, 79–84. [Google Scholar] [CrossRef] [PubMed]
  55. Boczonadi, V.; Muller, J.S.; Pyle, A.; Munkley, J.; Dor, T.; Quartararo, J.; Ferrero, I.; Karcagi, V.; Giunta, M.; Polvikoski, T.; et al. EXOSC8 mutations alter mRNA metabolism and cause hypomyelination with spinal muscular atrophy and cerebellar hypoplasia. Nat. Commun. 2014, 5, 4287. [Google Scholar] [CrossRef] [PubMed]
  56. Burns, D.T.; Donkervoort, S.; Muller, J.S.; Knierim, E.; Bharucha-Goebel, D.; Faqeih, E.A.; Bell, S.K.; AlFaifi, A.Y.; Monies, D.; Millan, F.; et al. Variants in EXOSC9 disrupt the RNA exosome and result in cerebellar atrophy with spinal motor neuronopathy. Am. J. Hum. Genet. 2018, 102, 858–873. [Google Scholar] [CrossRef] [PubMed]
  57. Bizzari, S.; Hamzeh, A.R.; Mohamed, M.; Al-Ali, M.T.; Bastaki, F. Expanded PCH1D phenotype linked to EXOSC9 mutation. Eur. J. Med. Genet. 2020, 63, 103622. [Google Scholar] [CrossRef] [PubMed]
  58. Charlesworth, G.; Balint, B.; Mencacci, N.E.; Carr, L.; Wood, N.W.; Bhatia, K.P. SLC25A46 mutations underlie progressive myoclonic ataxia with optic atrophy and neuropathy. Mov. Disord. 2016, 31, 1249–1251. [Google Scholar] [CrossRef] [PubMed]
  59. Hammer, M.B.; Ding, J.; Mochel, F.; Eleuch-Fayache, G.; Charles, P.; Coutelier, M.; Gibbs, J.R.; Arepalli, S.K.; Chong, S.B.; Hernandez, D.G.; et al. SLC25A46 mutations associated with autosomal recessive cerebellar ataxia in north african families. Neurodegener. Dis. 2017, 17, 208–212. [Google Scholar] [CrossRef] [PubMed]
Genes 16 00585 g001
Figure 1. PCH1-associated genes and mitochondrial dysfunction. Legend: Loss of function of VRK1, EXOSC3/8/9 and SLC25A46 is associated with mitochondrial dysfunction manifesting with depletion of mitochondrial DNA, promotion of mitochondrial hyperfusion and loss of mitochondrial reserve capacity [22,41,42].
Figure 1. PCH1-associated genes and mitochondrial dysfunction. Legend: Loss of function of VRK1, EXOSC3/8/9 and SLC25A46 is associated with mitochondrial dysfunction manifesting with depletion of mitochondrial DNA, promotion of mitochondrial hyperfusion and loss of mitochondrial reserve capacity [22,41,42].
Genes 16 00585 g001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Škarica, M.; Acsadi, G.; Živković, S.A. Pontocerebellar Hypoplasia Type 1 and Associated Neuronopathies. Genes 2025, 16, 585. https://doi.org/10.3390/genes16050585

AMA Style

Škarica M, Acsadi G, Živković SA. Pontocerebellar Hypoplasia Type 1 and Associated Neuronopathies. Genes. 2025; 16(5):585. https://doi.org/10.3390/genes16050585

Chicago/Turabian Style

Škarica, Mario, Gyula Acsadi, and Sasha A. Živković. 2025. "Pontocerebellar Hypoplasia Type 1 and Associated Neuronopathies" Genes 16, no. 5: 585. https://doi.org/10.3390/genes16050585

APA Style

Škarica, M., Acsadi, G., & Živković, S. A. (2025). Pontocerebellar Hypoplasia Type 1 and Associated Neuronopathies. Genes, 16(5), 585. https://doi.org/10.3390/genes16050585

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop